Biotech · Private company
Epizyme, Inc.
Track this companyFree. Adds Epizyme, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials257 recruiting or active
Pipeline programs31From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline31
- LenalidomidePhase 3 · Relapsed/Refractory Follicular LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- RituximabPhase 3 · Relapsed/Refractory Follicular LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- TazemetostatPhase 3 · Relapsed/Refractory Follicular LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- Abiraterone/prednisonePhase 2 · Metastatic Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- AcalabrutinibPhase 2 · Relapsed Hematologic MalignancyClinicalTrials.gov · fetched Nov 12, 2026
- Daratumumab (Intravenously)Phase 2 · Relapsed Hematologic MalignancyClinicalTrials.gov · fetched Nov 12, 2026
- EnzalutamidePhase 2 · Metastatic Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- LenalidomidePhase 2 · Relapsed Hematologic MalignancyClinicalTrials.gov · fetched Nov 12, 2026
- MosunetuzumabPhase 2 · Relapsed Hematologic MalignancyClinicalTrials.gov · fetched Nov 12, 2026
- PrednisolonePhase 2 · B-cell Lymphomas (Phase 1)ClinicalTrials.gov · fetched Nov 12, 2026
- RituximabPhase 2 · Follicular LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- TafasitamabPhase 2 · Relapsed Hematologic MalignancyClinicalTrials.gov · fetched Nov 12, 2026
- TazemetostatPhase 2 · Malignant Rhabdoid Tumors (MRT)ClinicalTrials.gov · fetched Nov 12, 2026
- TazemetostatPhase 2 · Relapsed Hematologic MalignancyClinicalTrials.gov · fetched Nov 12, 2026
- TazemetostatPhase 2 · B-cell Lymphomas (Phase 1)ClinicalTrials.gov · fetched Nov 12, 2026
- TazemetostatPhase 2 · Metastatic Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- TazemetostatPhase 2 · Diffuse Large B-cell Lymphoma (DLBCL)ClinicalTrials.gov · fetched Nov 12, 2026
- TazemetostatPhase 2 · Follicular LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- Doxorubicin HClPhase 1 · Advanced Soft-tissue SarcomaClinicalTrials.gov · fetched Nov 12, 2026
- EPZ-5676Phase 1 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- EZM0414Phase 1 · Multiple Myeloma, RefractoryClinicalTrials.gov · fetched Nov 12, 2026
- FluconazolePhase 1 · Diffuse Large B Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- ItraconazolePhase 1 · All MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- OmeprazolePhase 1 · Diffuse Large B Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- RepaglinidePhase 1 · Diffuse Large B Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- RifampinPhase 1 · All MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- TazemetostatPhase 1 · Hepatic ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- TazemetostatPhase 1 · Diffuse Large B Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- TazemetostatPhase 1 · All MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- TazemetostatPhase 1 · Advanced Soft-tissue SarcomaClinicalTrials.gov · fetched Nov 12, 2026
- TazemetostatPhase 1 · Rhabdoid TumorsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- Study of Tazemetostat in Lymphoid MalignanciesPHASE1 · TERMINATED · started Sep 5, 2024ClinicalTrials.gov NCT05983965 · fetched Nov 12, 2026
- A Study of Tazemetostat (Tazverik) Before Prostatectomy in Men With Prostate CancerEARLY_PHASE1 · WITHDRAWN · started Dec 1, 2023ClinicalTrials.gov NCT05567679 · fetched Nov 12, 2026
- Tazemetostat and Mosunetuzumab in Untreated Follicular LymphomaPHASE2 · ACTIVE_NOT_RECRUITING · started Nov 1, 2023ClinicalTrials.gov NCT05994235 · fetched Nov 12, 2026
- A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell LymphomasPHASE1 · ACTIVE_NOT_RECRUITING · started Oct 4, 2023ClinicalTrials.gov NCT05934838 · fetched Nov 12, 2026
- Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def TumorsPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Aug 10, 2023ClinicalTrials.gov NCT05407441 · fetched Nov 12, 2026
- Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin LymphomaPHASE1 · TERMINATED · started Jun 7, 2023ClinicalTrials.gov NCT05618366 · fetched Nov 12, 2026
- A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular LymphomaPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jan 26, 2023ClinicalTrials.gov NCT05551936 · fetched Nov 12, 2026
- A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell LymphomaPHASE1 · TERMINATED · started May 31, 2022ClinicalTrials.gov NCT05121103 · fetched Nov 12, 2026
- A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.PHASE1_PHASE2 · WITHDRAWN · started Dec 22, 2021ClinicalTrials.gov NCT05205252 · fetched Nov 12, 2026
- Tazemetostat in Malignant Peripheral Nerve Sheath TumorsPHASE2 · ACTIVE_NOT_RECRUITING · started Aug 25, 2021ClinicalTrials.gov NCT04917042 · fetched Nov 12, 2026
- Phase Ia/Ib Talazoparib + Tazemetostat for mCRPCPHASE1 · ACTIVE_NOT_RECRUITING · started Jun 28, 2021ClinicalTrials.gov NCT04846478 · fetched Nov 12, 2026
- Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell CarcinomaPHASE1 · TERMINATED · started Apr 14, 2021ClinicalTrials.gov NCT04624113 · fetched Nov 12, 2026
- SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular LymphomaPHASE2 · TERMINATED · started Dec 15, 2020ClinicalTrials.gov NCT04762160 · fetched Nov 12, 2026
- A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.PHASE3 · ACTIVE_NOT_RECRUITING · started Jun 11, 2020ClinicalTrials.gov NCT04224493 · fetched Nov 12, 2026
- Effects of Itraconazole and Rifampin on the Blood Tazemetostat LevelsPHASE1 · COMPLETED · started Apr 23, 2020ClinicalTrials.gov NCT04537715 · fetched Nov 12, 2026
- A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver FunctionPHASE1 · TERMINATED · started Jan 15, 2020ClinicalTrials.gov NCT04241835 · fetched Nov 12, 2026
- Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid SarcomaPHASE1 · TERMINATED · started Dec 19, 2019ClinicalTrials.gov NCT04204941 · fetched Nov 12, 2026
- A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate CancerPHASE1_PHASE2 · TERMINATED · started Nov 18, 2019ClinicalTrials.gov NCT04179864 · fetched Nov 12, 2026
- Epithelioid Sarcoma Natural History StudyCOMPLETED · started Jun 4, 2018ClinicalTrials.gov NCT03837678 · fetched Nov 12, 2026
- Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor PatientsPHASE1 · COMPLETED · started Mar 27, 2017ClinicalTrials.gov NCT03028103 · fetched Nov 12, 2026
- A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical StudyPHASE1_PHASE2 · TERMINATED · started Aug 30, 2016ClinicalTrials.gov NCT02875548 · fetched Nov 12, 2026
- EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial SarcomaPHASE1 · COMPLETED · started Jan 7, 2016ClinicalTrials.gov NCT02601937 · fetched Nov 12, 2026
- A Study of Tazemetostat in Adult Participants With Soft Tissue SarcomaPHASE2 · COMPLETED · started Dec 22, 2015ClinicalTrials.gov NCT02601950 · fetched Nov 12, 2026
- Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCLPHASE1_PHASE2 · COMPLETED · started Jun 13, 2013ClinicalTrials.gov NCT01897571 · fetched Nov 12, 2026
- A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias InvolvingPHASE1 · COMPLETED · started Sep 1, 2012ClinicalTrials.gov NCT01684150 · fetched Nov 12, 2026